10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Ecological research suggests that increased access to cannabis may facilitate reductions in opioid use and harms, and medical cannabis patients describe the substitution of opioids with cannabis for pain management. However, there is a lack of research using individual-level data to explore this question. We aimed to investigate the longitudinal association between frequency of cannabis use and illicit opioid use among people who use drugs (PWUD) experiencing chronic pain.

          Methods and findings

          This study included data from people in 2 prospective cohorts of PWUD in Vancouver, Canada, who reported major or persistent pain from June 1, 2014, to December 1, 2017 ( n = 1,152). We used descriptive statistics to examine reasons for cannabis use and a multivariable generalized linear mixed-effects model to estimate the relationship between daily (once or more per day) cannabis use and daily illicit opioid use. There were 424 (36.8%) women in the study, and the median age at baseline was 49.3 years (IQR 42.3–54.9). In total, 455 (40%) reported daily illicit opioid use, and 410 (36%) reported daily cannabis use during at least one 6-month follow-up period. The most commonly reported therapeutic reasons for cannabis use were pain (36%), sleep (35%), stress (31%), and nausea (30%). After adjusting for demographic characteristics, substance use, and health-related factors, daily cannabis use was associated with significantly lower odds of daily illicit opioid use (adjusted odds ratio 0.50, 95% CI 0.34–0.74, p < 0.001). Limitations of the study included self-reported measures of substance use and chronic pain, and a lack of data for cannabis preparations, dosages, and modes of administration.

          Conclusions

          We observed an independent negative association between frequent cannabis use and frequent illicit opioid use among PWUD with chronic pain. These findings provide longitudinal observational evidence that cannabis may serve as an adjunct to or substitute for illicit opioid use among PWUD with chronic pain.

          Abstract

          M-J Milloy and colleagues investigate use of cannabis and illicit opioids among people who use drugs reporting chronic pain.

          Author summary

          Why was this study done?
          • High numbers of people who use (illicit) drugs (PWUD) experience chronic pain, and previous research shows that illicit use of opioids (e.g., heroin use, non-prescribed use of painkillers) is a common pain management strategy in this population.

          • Previous research has suggested that some patients might substitute opioids (i.e., prescription painkillers) with cannabis (i.e., marijuana) to treat pain.

          • Research into cannabis as a potential substitute for illicit opioids among PWUD is needed given the high risk of opioid overdose in this population.

          • We conducted this study to understand if cannabis use is related to illicit opioid use among PWUD who report living with chronic pain in Vancouver, Canada, where cannabis is abundant and the rate of opioid overdose is at an all-time high.

          What did the researchers do and find?
          • Using data from 2 large studies of PWUD in Vancouver, Canada, we analyzed information from 1,152 PWUD who were interviewed at least once and reported chronic pain at some point between June 2014 and December 2017.

          • We used statistical modelling to estimate the odds of daily opioid use for (1) daily and (2) occasional users of cannabis relative to non-users of cannabis, holding other factors (e.g., sex, race, age, use of other drugs, pain severity) equal.

          • For participants who reported cannabis use, we also analyzed their responses to a question about why they were using cannabis (e.g., for intoxication, for pain relief)

          • We found that people who used cannabis every day had about 50% lower odds of using illicit opioids every day compared to cannabis non-users. People who reported occasional use of cannabis were not more or less likely than non-users to use illicit opioids on a daily basis. Daily cannabis users were more likely than occasional cannabis users to report a number of therapeutic uses of cannabis including for pain, nausea, and sleep.

          What do these findings mean?
          • Although more experimental research (e.g., randomized controlled trial of cannabis coupled with low-dose opioids to treat chronic pain among PWUD) is needed, these findings suggest that some PWUD with pain might be using cannabis as a strategy to alleviate pain and/or reduce opioid use.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: found

          The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction

          Annual Review of Public Health, 36(1), 559-574
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Self-report among injecting drug users: a review.

            The use of behavioural self-reports of drug users is widespread among studies of illicit drug use. Despite widespread use, concerns about the accuracy of these reports continue to be raised. The current paper critically reviews the literature on the reliability and validity of self-reported drug use, criminality and HIV risk-taking among injecting drug users. The literature shows respectable reliability and validity of self-reported behaviours when compared to biomarkers, criminal records and collateral interviews. It concludes that the self-reports of drug users are sufficiently reliable and valid to provide descriptions of drug use, drug-related problems and the natural history of drug use.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.

              Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them.
                Bookmark

                Author and article information

                Contributors
                Role: ConceptualizationRole: Formal analysisRole: InvestigationRole: MethodologyRole: VisualizationRole: Writing – original draftRole: Writing – review & editing
                Role: ConceptualizationRole: MethodologyRole: Writing – review & editing
                Role: Funding acquisitionRole: SupervisionRole: Writing – review & editing
                Role: ConceptualizationRole: Writing – review & editing
                Role: ConceptualizationRole: SupervisionRole: Writing – review & editing
                Role: Funding acquisitionRole: InvestigationRole: SupervisionRole: Writing – review & editing
                Role: ConceptualizationRole: Writing – review & editing
                Role: ConceptualizationRole: Funding acquisitionRole: InvestigationRole: MethodologyRole: SupervisionRole: Writing – review & editing
                Role: Academic Editor
                Journal
                PLoS Med
                PLoS Med
                plos
                plosmed
                PLoS Medicine
                Public Library of Science (San Francisco, CA USA )
                1549-1277
                1549-1676
                19 November 2019
                November 2019
                : 16
                : 11
                : e1002967
                Affiliations
                [1 ] British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada
                [2 ] School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
                [3 ] Department of Psychology, University of British Columbia, Kelowna, British Columbia, Canada
                [4 ] Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
                [5 ] Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, United States of America
                [6 ] British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
                [7 ] Department of Family Medicine, McGill University, Montreal, Québec, Canada
                [8 ] Department of Anesthesia, McGill University, Montreal, Québec, Canada
                Massachusetts General Hospital, UNITED STATES
                Author notes

                I have read the journal's policy and the authors of this manuscript have the following competing interests: M-JM is the Canopy Growth professor of cannabis science at UBC, a position created using unstructured arms’ length gifts to the university from Canopy Growth Corporation and the Government of British Columbia’s Ministry of Mental Health and Addictions. The University of British Columbia has received unstructured funding from NG Biomed, Ltd., an applicant to the Canadian federal government for a license to produce cannabis, to support M-JM. ZW is Coordinating Principal Investigator on a clinical trial sponsored by Tilray, a licensed producer of medical cannabis. ZDC has received research funds and partial salary support from Insys Therapeutics. She has served as a consultant to GB Sciences and Beckley Canopy Therapeutics and is a scientific advisor to FSD Pharma. MAW has consulted for CHI, CannaRoyalty and Zynerba and has received a grant to his institution for clinical research from CanniMed. He was appointed to Chief Medical Officer at Canopy Growth Corp in July 2018 (after the study period ended). He supported the first author in conceptualization of the research, but did not contribute to the study’s methodological design or data analysis. All other authors report no competing interests in relation to the work described.

                Author information
                http://orcid.org/0000-0002-0870-7153
                http://orcid.org/0000-0002-1286-1719
                http://orcid.org/0000-0003-3821-6221
                Article
                PMEDICINE-D-19-02142
                10.1371/journal.pmed.1002967
                6863529
                31743343
                1ead6c8f-a7a8-4da4-b2f9-558251fc4bd8
                © 2019 Lake et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 13 June 2019
                : 16 October 2019
                Page count
                Figures: 1, Tables: 2, Pages: 16
                Funding
                Funded by: funder-id http://dx.doi.org/10.13039/100000026, National Institute on Drug Abuse;
                Award ID: U01-DA038886
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/100000026, National Institute on Drug Abuse;
                Award ID: U01-DA021525
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000101, Pierre Elliott Trudeau Foundation;
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award Recipient :
                Funded by: funder-id http://dx.doi.org/10.13039/501100000245, Michael Smith Foundation for Health Research;
                Award Recipient :
                This study is supported by the US National Institutes on Drug Abuse ( https://www.drugabuse.gov; award numbers U01DA038886 [VIDUS, PI: TK] and U01DA021525 [ACCESS, PI: M-JM]). SL is supported through doctoral award funding from the Canadian Institutes of Health Research (CIHR; http://www.cihr-irsc.gc.ca) and the Pierre Elliott Trudeau Foundation ( http://www.trudeaufoundation.ca/en). M-JM is supported a New Investigator Award from CIHR and a Scholar Award from the Michael Smith Foundation for Health Research ( https://www.msfhr.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
                Categories
                Research Article
                Medicine and Health Sciences
                Pharmacology
                Behavioral Pharmacology
                Recreational Drug Use
                Cannabis
                Medicine and Health Sciences
                Pharmacology
                Drugs
                Analgesics
                Opioids
                Medicine and Health Sciences
                Pain Management
                Analgesics
                Opioids
                Medicine and Health Sciences
                Pharmacology
                Drugs
                Opioids
                Medicine and Health Sciences
                Pain Management
                Biology and Life Sciences
                Psychology
                Addiction
                Addicts
                Drug Users
                Social Sciences
                Psychology
                Addiction
                Addicts
                Drug Users
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Immunodeficiency Viruses
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Immunodeficiency Viruses
                HIV
                Biology and life sciences
                Organisms
                Viruses
                RNA viruses
                Retroviruses
                Lentivirus
                HIV
                Biology and Life Sciences
                Microbiology
                Medical Microbiology
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Pathogens
                Microbial Pathogens
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Biology and Life Sciences
                Organisms
                Viruses
                Viral Pathogens
                Retroviruses
                Lentivirus
                HIV
                Medicine and Health Sciences
                Pharmacology
                Behavioral Pharmacology
                Recreational Drug Use
                Heroin
                Medicine and Health Sciences
                Pharmacology
                Behavioral Pharmacology
                Recreational Drug Use
                Medicine and Health Sciences
                Diagnostic Medicine
                Signs and Symptoms
                Pain
                Neuropathic Pain
                Medicine and Health Sciences
                Pathology and Laboratory Medicine
                Signs and Symptoms
                Pain
                Neuropathic Pain
                Custom metadata
                Data cannot be shared publicly as this is not permitted under the parameters of our research ethics approval. Requests for anonymized data can be made to the University of British Columbia/ Providence Health Care Research Ethics Board (contact via the research administration office of the British Columbia Centre on Substance Use: inquiries@ 123456bccsu.ubc.ca ) by researchers who meet specific criteria set in the relevant ethics approval.

                Medicine
                Medicine

                Comments

                Comment on this article